Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00314210 · ClinicalTrials.gov registry record · Phase 3

Safety and Efficacy Maintenance Study of Quetiapine SR to Treat GAD Patients.

A Phase 3 study of Anxiety Disorders, sponsored by AstraZeneca.

Completed
Registry status
Phase 3
Development phase
575
Enrollment target
20
Study locations

NCT00314210 is a Phase 3 study of Anxiety Disorders that has completed, run by AstraZeneca. The registered enrollment target is 575 participants, below the 1,133-participant average among 84 other Anxiety Disorders trials with a reported enrollment target (49% lower). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00314210, a Phase 3 study of Anxiety Disorders, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 3
Development phase
575 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of this study is to evaluate the efficacy of quetiapine SR compared to placebo in increasing time from randomisation to an anxiety event in patients with generalised anxiety disorder (GAD). PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Conditions Studied

Anxiety Disorders

Interventions

  • DRUG Quetiapine SR

Study Locations (20)

Florida

  • Research Site - Coral Springs
  • Research Site - DeLand
  • Research Site - Fort Myers
  • Research Site - Gainsville
  • Research Site - Hialeah
  • Research Site - Jacksonville
  • Research Site - North Miami
  • Research Site - Orlando
  • Research Site - Saint Petersberg

California

  • Research Site - Fresno
  • Research Site - La Mesa
  • Research Site - Oceanside
  • Research Site - Redlands

Georgia

  • Research Site - Atlanta
  • Research Site - Columbus
  • Research Site - Marietta
  • Research Site - Roswell

Arizona

  • Research Site - Mesa
  • Research Site - Peoria
  • Research Site - Phoenix

Trial Details

FieldValue
Enrollment Target 575 participants
Start Date 2006-03
Est. Completion 2007-08
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00314210

The ClinicalTrials.gov registry entry for NCT00314210 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 575 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,133-participant average among 84 other Anxiety Disorders trials with a reported enrollment target (49% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Anxiety Disorders appearing as the primary indexed condition, and to 1 intervention - of which Quetiapine SR is the first listed.

NCT00314210 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Florida, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT00314210 about?

NCT00314210 is a clinical study titled "Safety and Efficacy Maintenance Study of Quetiapine SR to Treat GAD Patients.". The primary objective of this study is to evaluate the efficacy of quetiapine SR compared to placebo in increasing time from randomisation to an anxiety event in patients with generalised anxiety disorder (GAD). PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designat...

What is the current status of trial NCT00314210?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 575 participants. The study started on 2006-03. Estimated completion is 2007-08.

What conditions does trial NCT00314210 study?

This clinical trial studies the following conditions: Anxiety Disorders.

What interventions are being tested in trial NCT00314210?

The interventions under investigation include: Quetiapine SR (DRUG).

Who is sponsoring clinical trial NCT00314210?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00314210 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Anxiety Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Anxiety Disorders

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.